Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Today's Research: Amgen Inc., BioCryst Pharmaceuticals Inc., PDL BioPharma Inc., and Questcor Pharmaceuticals Inc.



  Today's Research: Amgen Inc., BioCryst Pharmaceuticals Inc., PDL BioPharma
                   Inc., and Questcor Pharmaceuticals Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, September 20, 2013

LONDON, September 20, 2013 /PRNewswire/ --

On Thursday, September 19, 2013, the U.S equity markets ended on a mixed note
with the S&P 500 closing at 1,722.34, down 0.18%; the Dow Jones Industrial
Average ending at 15,636.55, down 0.26%; while the NASDAQ Composite closed at
3,789.38, up 0.15%. Shares in the biotechnology industry mostly ended lower,
even as the broader market finished on a mixed note. The major movers in the
sector included Amgen Inc. (NASDAQ: AMGN), BioCryst Pharmaceuticals Inc.
(NASDAQ: BCRX), PDL BioPharma Inc. (NASDAQ: PDLI), and Questcor
Pharmaceuticals Inc. (NASDAQ: QCOR). AAAResearchReports.com has completed
their technical analysis on AMGN, BCRX, PDLI, and QCOR and these free reports
are accessible by registering at:

http://www.aaaresearchreports.com/register/  

On Thursday, Amgen Inc.'s shares edged lower to end the day at $117.18, which
is 0.29% lower than the previous day's closing price of $117.52. The company's
shares fluctuated between $115.66 and $117.85 during the trading session. A
total of 3.03 million shares were traded, which is below the daily average
volume of 3.32 million. Despite Thursday's decline, Amgen Inc.'s shares have
surged 12.17% in the last one month and 18.15% in the previous three months,
outperforming the S&P 500 which has advanced 4.63% and 5.73% during the
respective periods. Further, the company's stock is trading near its 52-week
high of $117.91 as well as above its 50-day and 200-day moving averages of
$108.84 and $98.81, respectively. Sign up for free technical research on AMGN
at:

http://www.AAAResearchReports.com/AMGN092013.pdf

BioCryst Pharmaceuticals Inc.'s stock gained 0.74% on Thursday, even as the
broader market fluctuated between gains and losses. The company's shares
oscillated between $6.72 and $6.94 before finishing the day at $6.79. A total
of 1.08 million shares were traded, which is below the daily average volume of
2.44 million. Furthermore, BioCryst Pharmaceuticals Inc.'s stock is trading
near its 52-week high of $7.41 as well as above its 50-day and 200-day moving
average of $5.17 and $2.48, respectively. The company's shares have rallied
297.08% in the previous three months and 23.91% in the last one month,
compared to a gain of 5.73% and 4.63% in the S&P 500 during the same period.
Be sure to read our latest technical research on BCRX by registering at:

http://www.AAAResearchReports.com/BCRX092013.pdf

Shares in PDL BioPharma Inc. edged lower on Thursday, even as the broader
market ended on a mixed note. The company's shares fluctuated between $8.00
and $8.20 before closing the day 0.43% lower at $8.08. A total of 1.13 million
shares were traded, which is less than the daily average volume of 1.79
million. The company's shares have gained 2.54% in the previous three trading
sessions and 5.07% in the last three months, compared to a gain of 1.46% and
5.73% in the S&P 500 during the respective period. Further, PDL BioPharma
Inc.'s stock has moved closer to its 52-week high of $8.48 as well as above
its 50-day and 200-day moving averages of $8.06 and $7.61, respectively. Sign
up and read the complimentary report on PDLI at:

http://www.AAAResearchReports.com/PDLI092013.pdf

The Questcor Pharmaceuticals Inc.'s stock plummeted on Thursday, reversing all
gains from the previous trading session. The company's shares ended the day
7.54% lower at $60.68 after fluctuating between $60.56 and $65.77. A total of
2.61 million shares were traded, which is above the daily average volume of
1.59 million. Despite the recent losses, Questcor Pharmaceuticals Inc.'s
shares have rallied 27.86% in the previous three months, outperforming the S&P
500 which has advanced 5.73% during the same period. Additionally, the
company's stock is trading above its 200-day moving average of $39.56. The
free report on QCOR can be downloaded by signing up now at:

http://www.AAAResearchReports.com/QCOR092013.pdf

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AAAresearchreports.com

SOURCE AAA Research Reports

Contact: +1(646)396-9126, Peter F. Jones, info@aaaresearchreports.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement